CPMP konkluderede, at Medicinska födelseregistret giver et robust signal om, at eksponering for loratadin under graviditeten øger risikoen for hypospadi.
The CPMP concluded that the SMBR provides a robust signal that loratadine exposure during pregnancy increases the risk of hypospadia.